<--- Back to Details
First PageDocument Content
Immunotherapy / Tak Wah Mak / Cancer research / Cancer immunotherapy / Autoimmunity / T cell / Dendritic cell / C. Garrison Fathman / Lloyd J. Old / Medicine / Immunology / Biology
Date: 2014-01-01 20:27:10
Immunotherapy
Tak Wah Mak
Cancer research
Cancer immunotherapy
Autoimmunity
T cell
Dendritic cell
C. Garrison Fathman
Lloyd J. Old
Medicine
Immunology
Biology

Congratulations / Félicitations Dr. Pamela S. Ohashi, University of Toronto The 2014 CSI – Hardy Cinader Award Recipient Presentation: “From Y Y Z and beyond” Director, Immune Therapy Program, Ontario Cancer Insti

Add to Reading List

Source URL: www.csi-sci.ca

Download Document from Source Website

File Size: 107,99 KB

Share Document on Facebook

Similar Documents

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

DocID: 1uTyz - View Document

FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

DocID: 1tGAn - View Document

Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

DocID: 1tBVB - View Document